EUIPO sides with Takeda in trademark appeal
28-11-2018
AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug
29-08-2017
Jonathan Weiss / Shutterstock.com
Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Takeda, Par Pharmaceuticals, US District Court for the District of Massachusetts, FWK Holdings, Amitza
